SMS Lifesciences India gets nod to divest partial equity shares in Mahi Drugs

01 Dec 2021 Evaluate

SMS Lifesciences India has received approval to divest partial equity shares in Mahi Drugs -- wholly owned subsidiary of the Company, not exceeding 10%, by way of sale of equity shares held by the Company, to ChemWerth Inc, USA, Strategic Investor.

Upon completion of the transactions, Mahi Drugs will cease to be a wholly-owned subsidiary of the Company, but shall continue as a Subsidiary Company with 60% stake of the post issued capital, with the Company. The board of directors at its meeting held on November 30, 2021 has considered and approved the same.

SMS Lifesciences India is presently engaged in the business of manufacturing, buying, selling, offering consultancy, importing and exporting, acting as commission agents and generally dealing with of all types of Organic & Inorganic Chemicals, Pharmaceuticals, API and Intermediates.

Haleos Labs Share Price

1335.00 16.20 (1.23%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×